John Goldberg
Chief Tech/Sci/R&D Officer bij RAFAEL HOLDINGS, INC.
Vermogen: 344 $ op 31-12-2023
Profiel
John M.
Goldberg is currently the Chief Medical Officer at Rafael Holdings, Inc. Prior to this, he was the Chief Medical Officer at Oncorus, Inc. from 2018 to 2023.
He also held the position of Senior Director-Medical at H3 Biomedicine, Inc. and Head-Clinical Development at Agenus, Inc. Dr. Goldberg received his undergraduate degree from The University of Chicago and his doctorate from the University of Massachusetts Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ONCORUS, INC.
0.01% | 31-03-2023 | 2 730 ( 0.01% ) | 344 $ | 31-12-2023 |
Actieve functies van John Goldberg
| Bedrijven | Functie | Begin |
|---|---|---|
| RAFAEL HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 20-11-2023 |
Eerdere bekende functies van John Goldberg
| Bedrijven | Functie | Einde |
|---|---|---|
| ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 30-06-2023 |
| AGENUS INC. | Chief Tech/Sci/R&D Officer | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - |
Opleiding van John Goldberg
| The University of Chicago | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AGENUS INC. | Health Technology |
| RAFAEL HOLDINGS, INC. | Finance |
| Bedrijven in privébezit | 2 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
| Oncorus, Inc. |
